ClinicalTrials.gg
CompletedNCT05866627Updated May 13, 2026

A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants

A Phase 1 interventional study of Famotidine and Afimetoran in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to confirm there is no significant effect of gastric pH changes of famotidine on the drug levels of afimetoran in healthy participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • BMS-986256
  • Famotidine
  • Gastric pH
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weight ≥ 50 kilograms (kg), at screening and first admission, and between 18.0 kilogram per square meter (kg/m\^2) and 32.0 kg/m\^2, inclusive, at screening.
  • A negative QuantiFERON-TB Gold test result at screening or documentation of a negative result within 3 months before screening.
  • Normal renal function at screening as evidenced by an estimated (eGFR) ≥ 80 milliliter per minute (mL/min)/1.732 m\^2 calculated with the Chronic Kidney Disease Epidemiology Collaboration formula.

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness.
  • Current or recent (within 3 months of study drug administration) gastrointestinal (GI) disease that could impact upon the absorption of study treatment.
  • GI surgery, including cholecystectomy, that could impact upon the absorption of study treatment, at the investigator's discretion.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Afimetoran, followed by famotidine + afimetoran

    Drug: Famotidine · Drug: Afimetoran

  • Experimental
    Famotidine + afimetoran, followed by afimetoran

    Drug: Famotidine · Drug: Afimetoran

  • Experimental
    Afimetoran

    Drug: Afimetoran

  • Experimental
    Famotidine, followed by afimetoran

    Drug: Famotidine · Drug: Afimetoran

Interventions

  • Specified dose on specified days

    Also known as: Pepcid

  • Specified dose on specified days

    Also known as: BMS-986256

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to 20 Days

  2. Time to attain maximum observed plasma concentration (Tmax)

    Time frame: Up to 20 Days

  3. Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC[0-T])

    Time frame: Up to 20 Days

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 52 Days

  2. Number of participants with clinical laboratory abnormalities

    Time frame: Up to 52 Days

  3. Number of participants with vital sign abnormalities

    Time frame: Up to 52 Days

  4. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to 52 Days

07

Study locations

1 site
  • Local Institution - 0001
    Nottingham, Nottinghamshire NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Sep 2023, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2023
First posted
May 19, 2023
StartActual
Jul 4, 2023
Primary completionActual
Sep 29, 2023
CompletionActual
Sep 29, 2023
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05866627
Responsible party
Sponsor
First posted
May 19, 2023
Start date
Jul 4, 2023
Primary completion
Sep 29, 2023
Completion
Sep 29, 2023
Last update
May 13, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimetoran

Start the discussion